CA2136091A1 - Combinaisons medicamenteuses chimiotherapeutiques - Google Patents

Combinaisons medicamenteuses chimiotherapeutiques

Info

Publication number
CA2136091A1
CA2136091A1 CA002136091A CA2136091A CA2136091A1 CA 2136091 A1 CA2136091 A1 CA 2136091A1 CA 002136091 A CA002136091 A CA 002136091A CA 2136091 A CA2136091 A CA 2136091A CA 2136091 A1 CA2136091 A1 CA 2136091A1
Authority
CA
Canada
Prior art keywords
inhibitor
tumor
group
administering
mmpr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002136091A
Other languages
English (en)
Inventor
Daniel S. Martin
Robert L. Stolfi
Joseph R. Colofiore
L. D. Nord
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pro Neuron Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2136091A1 publication Critical patent/CA2136091A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002136091A 1992-05-20 1993-05-20 Combinaisons medicamenteuses chimiotherapeutiques Abandoned CA2136091A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88580992A 1992-05-20 1992-05-20
US07/885,809 1992-05-20

Publications (1)

Publication Number Publication Date
CA2136091A1 true CA2136091A1 (fr) 1993-11-25

Family

ID=25387744

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002136091A Abandoned CA2136091A1 (fr) 1992-05-20 1993-05-20 Combinaisons medicamenteuses chimiotherapeutiques

Country Status (5)

Country Link
EP (1) EP0641193A4 (fr)
JP (1) JPH08506317A (fr)
AU (1) AU684709B2 (fr)
CA (1) CA2136091A1 (fr)
WO (1) WO1993023014A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
EP1171118A2 (fr) * 1999-04-09 2002-01-16 Jessie L.S. Au Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus
EP1349555A4 (fr) * 2000-12-04 2007-04-25 Sloan Kettering Inst Cancer Traitement du cancer par reduction d'energie intracellulaire et a l'aide de pyrimidines
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
AU2002342808A1 (en) * 2002-10-09 2004-05-04 Unibioscreen S.A. Extract with anti-tumor and anti-poisonous activity
EP2711009A1 (fr) * 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Composés destinés à être utilisés dans le traitement ou la prévention du cancer primitif et métastatique du sein et de la prostate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55106517A (en) * 1979-02-08 1980-08-15 Daido Steel Co Ltd Convering of adsorption and deodorization vessel
JPS5637025A (en) * 1979-08-30 1981-04-10 Mitsubishi Electric Corp Deodorizing system
US5114951A (en) * 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance

Also Published As

Publication number Publication date
EP0641193A4 (fr) 1995-09-06
EP0641193A1 (fr) 1995-03-08
AU684709B2 (en) 1998-01-08
AU4383493A (en) 1993-12-13
JPH08506317A (ja) 1996-07-09
WO1993023014A1 (fr) 1993-11-25

Similar Documents

Publication Publication Date Title
Lui et al. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
Hertel et al. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine)
Cronstein et al. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine
Nutter et al. Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines
Cohen et al. Cardioprotective PKG-independent NO signaling at reperfusion
Kitamura et al. Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat
US20030125298A1 (en) Cancer therapy comprising deaminase enzyme inhibitors
CN101820883B (zh) A3ar激动剂在用于制备刺激肝细胞增殖的药物中的应用
KR20060036490A (ko) 아데노신 수용체 아고니스트 또는 길항제를 포함하는 제약조성물
CA2317093A1 (fr) Agonistes de recepteur d'adenosine a2a
NZ561649A (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
Somberg et al. Localization of the neurally mediated arrhythmogenic properties of digitalis
AU2004216891B2 (en) Use of adenosine receptor agonists in therapy
Page et al. Principles of chemotherapy
CA2136091A1 (fr) Combinaisons medicamenteuses chimiotherapeutiques
JP2004502640A (ja) 肝繊維症、硬変症および脂肪肝を治療および予防するアデノシンａ２ａ受容体拮抗薬
Smolenski et al. Adenine/ribose supply increases adenosine production and protects ATP pool in adenosine kinase-inhibited cardiac cells
Naz et al. Pharmacological inhibition of HSP90 radiosensitizes head and neck squamous cell carcinoma xenograft by inhibition of DNA damage repair, nucleotide metabolism, and radiation-induced tumor vasculogenesis
US6608106B2 (en) Method for increasing the concentration of ascorbic acid in brain tissues of a subject
EP2636677B1 (fr) Dérivé de carboxamide de pyrrolopyrimidinone inhibant les cdk ou sel pharmaceutiquement acceptable de celui-ci, et composition pharmaceutique contenant ce dérivé comme principe actif et destinée à prévenir ou à traiter un carcinome hépatocellulaire
Tolcher et al. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Hirai et al. Modulation of adenosine effects in attenuation of ischemia and reperfusion injury in rat heart
CA2415793A1 (fr) Systemes d'apport de medicament a des hepatocytes et traitement d'infections a flaviviridae
US20040077563A1 (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
Modi et al. Single-agent gemcitabine in the treatment of advanced breast cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead